A Study of Chemotherapy Treatment for Patients With Ovarian Cancer

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

• At least 18 years old

• Have received at least one but no more than 2 systemic treatment regimens containing platinum (does not include regimens received before surgery for this cancer)

• Have platinum-resistant disease

Exclusion Criteria:

• Have received more than 2 systemic treatment regimens for platinum-resistant disease

• Serious pre-existing medical conditions

• Actively receiving warfarin (Coumadin) for treatment of venous thrombosis or other prothrombotic conditions